GoldenGolden
Zymeworks

Zymeworks

A company focused on the development on therapeutic antibodies and other protein-based therapeutics

Help us improve this page by adding information.
Visit our Writing Guide or this topic page for additional help.

Timeline

September 22, 2011
Zymeworks raises a $8,100,000 series D round.
June 26, 2009
Zymeworks raises a $3,500,000 series C round.
March 3, 2008
Zymeworks raises a $1,300,000 seed round.

Funding rounds

People

Name
Role
LinkedIn

Anders Ohrn

Employee

Anthony Fejes

Employee

Shayan Rahnama

Employee

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
April 19, 2021
BioSpace
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that Diana Hausman, M.D., will be transitioning out of her role as Zymeworks' Chief Medical Officer (CMO) and assuming an executive advisory role until November 15th, 2021.
Annalee Armstrong
April 19, 2021
FierceBiotech
Zymeworks CMO Diana Hausman, M.D., will pass the torch to Neil Josephson, M.D., who currently oversees the Canadian biotechnology company's global clinical studies.
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.